Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739996 · ClinicalTrials.gov registry record · Phase 2
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03739996 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants.
The verdict
NCT03739996, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
Interventions
- BIOLOGICAL VRC07-523LS
- DRUG Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- DRUG Oral Cabotegravir (CAB)
- DRUG Long-Acting Injectable Cabotegravir (CAB LA)
- DRUG Standard of Care (SOC) ART
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739996
The ClinicalTrials.gov registry entry for NCT03739996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which VRC07-523LS is the first listed.
NCT03739996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03739996 about?
NCT03739996 is a clinical study titled "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1". The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
What is the current status of trial NCT03739996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2019-12-31. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT03739996?
The interventions under investigation include: VRC07-523LS (BIOLOGICAL), Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (DRUG), Oral Cabotegravir (CAB) (DRUG), Long-Acting Injectable Cabotegravir (CAB LA) (DRUG), Standard of Care (SOC) ART (DRUG).
Who is sponsoring clinical trial NCT03739996?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.